Back to top

Image: Bigstock

BioDelivery Sciences International, Inc.

Read MoreHide Full Article

BioDelivery reported narrower-than-expected loss in third-quarter 2017 with revenues beating estimates. The company has secured improved positioning in six new managed care contracts providing preferred access to its key drug, Bunavail, since July last year. This is expected to boost the drug’s sales and profitability in turn. Meanwhile, its second marketed drug, Belbuca, recently received an approval in Canada for severe pain that should support further sales growth. BioDelivery’s shares have significantly outperformed the industry so far this year. However, the company suffered a setback with the discontinuation of clonidine topical gel for management of painful diabetic neuropathy in December 2016. BioDelivery’s portfolio as well as its pipeline candidates may also face a severe competition as it targets a highly genericized and crowded market.

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

BioDelivery Sciences International, Inc. (BDSI) - free report >>